Surgery for Stage IV Non-Small Cell Lung Cancer: Lobectomy or Sub-lobar Resection?

CURRENT STATUS: UNDER REVIEW

Hengrui Liang
Guangzhou Medical University

Yichi Zhang
Guangzhou Medical University

Wei Wang
Guangzhou Medical University

Jun Huang
Guangzhou Medical University

Fei Cui
Guangzhou Medical University

Bo Cheng
Guangzhou Medical University

Yi Zhao
Guangzhou Medical University

Shan Xiong
Guangzhou Medical University

Jianfu Li
Guangzhou Medical University

Caichen Li
Guangzhou Medical University

Jun Liu
Guangzhou Medical University

Jianxing He

drjianxing.he@gmail.com Corresponding Author
Abstract

**Background**: A survival benefit was observed in metastatic non-small cell lung cancer (NSCLC) patients that underwent operation. But no evidence to support whether lobectomy would further prolong these patients’ live than sub-lobar resection.

**Methods**: Patients that underwent primary tumor resection with metastatic NSCLC were identified from the Surveillance, Epidemiology and End Results (SEER) database and then divided into lobectomy and sub-lobar resection groups. A 1:1 propensity score matching (PSM) was performed to balance characters. Cancer specific survival (CSS) was estimated.

**Results**: A total of 24,268 patients with metastatic NSCLC were identified; 4,114 (16.95%) received primary tumor surgery, of which 2,045 (49.71%) underwent lobectomy and 1,766 (42.93%) underwent sub-lobar resection. After PSM, 644 patients in each group were included. Lobectomy was independently correlated with longer median CSS time (HR=0.70, 95% CI 0.61-0.80, P<0.001). The 1, 2 and 3-year survival rate after PSM also favored the lobectomy group. However, no significant survival difference was found in wedge resection and segmentectomy (HR=0.96, 95% CI 0.70-1.31, P=0.490). The 1, 2 and 3-year survival rate after PSM also showed no difference within the sub-lobar group. We explore whether lymph node dissection would provide a further survival benefit for stage IV NSCLC patients. According to the multivariate Cox analysis of the matched population, lymph node dissection was independently associated with better CSS (HR=0.76, 95% CI 0.66-0.88, P<0.001) and OS (HR=0.74, 95% CI 0.65-0.86, P<0.001). We confirmed this result in different types of surgery and found lymph node dissection group persist to have better survival outcomes both in lobectomy group and sub-lobar resection population. According to subgroup analysis, except for stage T4 and brain metastasis patients, all subtype of patients would benefit more from lobectomy than sub-lobar resection.

**Conclusions**: Lobectomy brings survival benefit in metastatic NSCLC patients compared with sub-lobar resection.

**Background**

Lung cancer is one of the leading causes of cancer death worldwide,[1] approximately 85% subtype
patients of which are non-small cell lung cancer (NSCLC) [2] The 5-year survival rate of these patients was only 4–6% and 40% of which were diagnosed as stage IV disease at the first visit to hospital.[3] The recommended treatment for stage IV NSCLC is systemic therapy (chemotherapy, molecular targeted therapy or immune therapy). [4] Traditionally, stage IV treatment strategy for NSCLC have not included curative-intent local therapy (surgery or radiation), given therapeutic goals which have focused on disease control, palliation and optimization of life quality. But more recently several clinical studies have shown that local consolidative therapy may be beneficial for stage IV non-small cell lung cancer (NSCLC) patients and improve their survival.[5, 6] Daniel et al.[7] conducted the first phase II clinical trial considering the effects of local consolidative therapy in combination with systemic treatment. The updated long-term outcomes indicated local consolidative therapy favored progression free survival (PFS) (14.2 months vs 4.4 months; p = 0.022) and overall survival (OS) (41.2 months vs 17.0 months; p = 0.017).

Lobectomy and systematic lymph node dissection is the cornerstone for early stage of NSCLC. Recently, evidences from real world studies showed primary tumor resection would also be beneficial for stage IV NSCLC patients and improve their survival.[8-10] However, no study explore which surgery type (lobectomy or sub-lobar resection) would provide more survival benefit for these patients.

To address this unresolved issue, we performed a population-based study to examine whether lobectomy or sub-lobar resection in stage IV NSCLC patients who underwent surgery with the most benefit.

Methods
SEER Database
The Surveillance, Epidemiology and End Results (SEER) database is a national population-based reporting system that collects tumor-related data, covering approximately 28% of the US population.[11] The SEER data is publicly available for studies of cancer-based epidemiology and survival analysis. We received permission to access the data used for this research (SEER-Stat username: 11136-Nov2018).
Cases of lung cancer (C34.0-34.9) diagnosed from 2004 to 2016 were extracted from the SEER database (SEER-Stat 8.3.6) according to the site code classifications. This range was selected because the American Joint Committee on Cancer (AJCC) TMN stage and Collaborative Stage (CS) information became available in 2004. We reclassified the TNM stage according to AJCC 8th edition. Patients who underwent primary tumor resection diagnosed at stage IV and histologically confirmed as NSCLC were enrolled. Patients were excluded if the surgery to primary site record was unknown. Other exclusion criteria were as follows: less than 18 years old, unknown TNM stage, unknown time of survival, unknown treatment modality, not the first tumor and not only one tumor.

**Statistical analysis**
The study sample was divided according to surgical resection strategy for primary tumor: Lobectomy versus sub-lobar resection. The propensity-score matching (PSM) generated from the logistic regression were performed to minimize the differences in confounding variables and facilitate matching patients in the two treatment groups (R software version 2.15.1, https://cran.r-project.org/). Variables that could influence the outcomes of treatment were used to generate a propensity score, including age, gender, histology, TNM stage, differentiation grade and tumor position. Patients were 1:1 matched on the basis of PSM using the nearest-neighbor method on the logit scale. The caliper was set at 0.01. After PSM, standardized mean differences (SMD) before and after PSM were calculated. Confounding variables was considered comparable when SMD below 0.10.

Overall survival (OS), cancer specific survival (CSS) and survival months were extracted from the SEER database. OS was the time from diagnosis to death from any cause; living patients were excluded at the time of last recording. CSS was calculated from the date of diagnosis to the date of cancer specific death. OS and CSS were estimated by the Kaplan- Meier (K-M) method and compared with the log-rank test. Univariate and multivariate Cox proportional hazard regression was used to determine independent prognostic factors. Hazard ratios (HRs) were calculated with 95% confidence interval (CI).

The normality of the data was assessed by the Shapiro-Wilk test. Continuous variables were given as mean and standard deviation. Student’s t-test or Mann-Whitney test was performed to compare
differences between groups with continuous variables. Distribution of categorical variables was presented as a count and percentage. The $\chi^2$ test or Fisher exact test for small samples was used to compare categorical variables. Subgroup analysis was conducted according to different clinical types of population. Statistical analysis was performed with SPSS 24.0 (IBM Corp., Armonk, NY, USA), statistical tests were two-sided, and $P < 0.05$ was considered statistically significant.

Results
Demographic characteristics before and after PSM

In total, 476,757 NSCLC patients were identified from 2004 to 2016 in the SEER database, of which, 24,268 stage IV NSCLC patients met the inclusion criteria, the screening process is shown in Fig. 1. Of all eligible patients, 4,114 (16.95%) underwent surgical treatment to primary tumor site, 2,045 (49.71%) of these patients underwent lobectomy and 1,766 (42.93%) received sub-lobar resection, others underwent pneumonectomy and biopsy, which were not included in this analysis. Obvious differences in age, histology, differentiation, tumor position, TNM stage, radiation chemotherapy and distant surgery were noted between the lobectomy and sub-lobar resection groups. (Table 1) This indicated that the baseline characteristics of the two groups were not balanced. Specifically, lobectomy group was associated with lower T stage patients. After the 1:1 PSM, 1,288 stage IV NSCLC patients treated with lobectomy ($n = 644$) or sub-lobar resection ($n = 644$) were enrolled in the survival analysis. Baseline characteristics were all well balanced (Table 1).
Table 1

Demographic Information for Patients with Stage IV NSCLC before and after PSM

|                   | Before PSM | After PSM |
|-------------------|------------|-----------|
|                   | Sub-lobectomy | Lobectomy | SMD | Sub-lobectomy | Lobectomy | SMD |
|                   | (n = 1766)  | (n = 2045) |     | (n = 644)  | (n = 644) |     |
| Age               |             |           |     |             |           |     |
| < 60              | 540 (30.6)  | 685 (33.5) | 0.566 | 201 (31.2)  | 184 (28.6) | < 0.001 |
| 60–75             | 879 (49.8)  | 1062 (51.9)|     | 326 (50.6)  | 342 (53.1) |     |
| > 75              | 347 (19.6)  | 298 (14.6) |     | 117 (18.2)  | 118 (18.3) |     |
| Gender            |             |           |     |             |           |     |
| Male              | 862 (48.8)  | 1008 (49.3)| < 0.001 | 322 (50.0)  | 309 (48.0) | < 0.001 |
| Female            | 904 (51.2)  | 1037 (50.7)|     | 322 (50.0)  | 335 (52.0) |     |
| Histology         |             |           |     |             |           |     |
| Squamous cell carcinoma | 205 (11.6)  | 336 (16.4) | 0.016 | 83 (12.9)   | 89 (13.8)  | < 0.001 |
| Adenocarcinoma    | 1330 (75.3)| 1312 (64.2)|     | 468 (72.7)  | 445 (69.1) |     |
| Other             | 231 (13.1)  | 397 (19.4) |     | 93 (14.4)   | 110 (17.1)|     |
| Differentiation   |             |           |     |             |           |     |
| Well              | 195 (11.1)  | 162 (7.9)  | 0.023 | 59 (9.2)    | 69 (10.7)  | < 0.001 |
| Moderately        | 541 (30.6)  | 628 (30.6) |     | 194 (30.1)  | 182 (28.3)|     |
| Poorly            | 595 (33.7)  | 905 (44.3) |     | 248 (38.5)  | 246 (38.2)|     |
| undifferentiated  | 55 (3.1)    | 81 (4.0)   |     | 23 (3.6)    | 26 (4.0)   |     |
| Unknown           | 380 (21.5)  | 269 (13.2) |     | 120 (18.6)  | 121 (18.8)|     |
| Position          |             |           |     |             |           |     |
| Bronchus          | 13 (0.7)    | 10 (0.5)   | 0.057 | 4 (0.6)     | 2 (0.3)    | < 0.001 |
| Lobe              | 1450 (82.1)| 1883 (92.1)|     | 557 (86.5)  | 558 (86.6)|     |
| Overlapping lesion| 35 (2.0)    | 52 (2.5)   |     | 11 (1.7)    | 16 (2.5)   |     |
| Unknown           | 268 (15.2)  | 100 (4.9)  |     | 72 (11.2)   | 68 (10.6)|     |
| AJCC T status     |             |           |     |             |           |     |
| T1                | 304 (17.2)  | 381 (18.6) | 0.497 | 138 (21.4)  | 158 (24.5)| < 0.001 |
| T2                | 375 (21.3)  | 872 (42.7) |     | 195 (30.3)  | 195 (30.3)|     |
| T3                | 308 (17.4)  | 350 (17.1) |     | 107 (16.6)  | 107 (16.6)|     |
| T4                | 779 (44.1)  | 442 (21.6) |     | 204 (31.7)  | 184 (28.6)|     |
| AJCC N status     |             |           |     |             |           |     |
| N0                | 947 (53.6)  | 1070 (52.3)| 0.148 | 340 (52.8)  | 364 (56.5)| 0.023 |
| N1                | 145 (8.2)   | 382 (18.7) |     | 64 (9.9)    | 77 (12.0)|     |
| N2                | 537 (30.4)  | 542 (26.5) |     | 205 (31.9)  | 170 (26.4)|     |
| N3                | 137 (7.8)   | 91 (2.5)   |     | 35 (5.4)    | 33 (5.1)|     |
| AJCC M status     |             |           |     |             |           |     |
| M1a               | 475 (26.9)  | 373 (18.3) | 0.856 | 141 (21.9)  | 149 (23.1)| < 0.001 |
| M1b               | 390 (22.1)  | 575 (28.1) |     | 148 (23.0)  | 148 (23.0)|     |
| M1                | 901 (51.0)  | 1097 (53.6)|     | 355 (55.1)  | 347 (53.9)|     |
| LN dissection     |             |           |     |             |           |     |
| No                | 1243 (70.5)| 231 (57.8) | 0.308 | 194 (30.1)  | 211 (32.8)| 0.041 |
| Yes               | 523 (29.5)  | 1814 (88.7)|     | 450 (69.9)  | 433 (67.2)|     |
| Radiation         |             |           |     |             |           |     |
| No                | 1245 (70.5)| 1181 (57.8)| 0.953 | 423 (65.7)  | 422 (65.5)| 0.002 |
| Yes               | 521 (29.5)  | 864 (42.2) |     | 221 (34.3)  | 222 (34.5)|     |
| Chemotherapy      |             |           |     |             |           |     |
| No/Unknown        | 722 (40.9)  | 892 (43.6) | 0.261 | 270 (41.9)  | 290 (45.0)| < 0.001 |
| Yes               | 1044 (59.1)| 1153 (56.4)|     | 374 (58.1)  | 354 (55.0)|     |
| Surgery to metastasis site | 1021 (57.8) | 1374 (67.2)| 0.118 | 313 (48.6)  | 359 (55.7)| 0.033 |
| PSM, propensity score matching; NSCLC, non-small cell lung cancer; LN, lymph node; AJCC, American Joint Committee on Cancer

Logistic analysis was performed to evaluate which variables were associated with lobectomy (Table 2). Compared with patients under 60 years old, patients over 75 years old tend to receive more sub-lobar resection than lobectomy (HR = 0.71, 95% CI 0.55–0.91, P = 0.007). In addition, T4 patients...
received less lobectomy compared with T1 or T2 patients. Patients who received radiation therapy also receive more lobectomy than patients with no radiotherapy (HR = 1.30, 95% CI 1.08–1.56, P = 0.005).

Table 2
Logistic Regression Model for stage IV NSCLC patients underwent lobectomy or sub-lobar resection

| Characteristic                  | Univariate Analysis | Multivariate Analysis |
|---------------------------------|--------------------|----------------------|
|                                 | Odds Ratios        | P Value              | Odds Ratios        | P Value              |
|                                 | (95%CI)            |                      | (95%CI)            |                      |
| Age                             |                    |                      |                    |                      |
| < 60                            | 1.00 (reference)   |                      | 1.00 (reference)   |                      |
| 60–75                           | 0.94 (0.78–1.34)   | 0.531                | 0.94 (0.78–1.14)   | 0.551                |
| > 75                            | 0.70 (0.54–0.90)   | 0.006                | 0.71 (0.55–0.91)   | 0.007                |
| Gender                          |                    |                      |                    |                      |
| Male                            | 1.00 (reference)   |                      |                    |                      |
| Female                          | 1.02 (0.86–1.20)   | 0.859                |                    |                      |
| Histology                       |                    |                      |                    |                      |
| Squamous cell carcinoma         | 1.00 (reference)   |                      | 1.00 (reference)   |                      |
| Adenocarcinoma                  | 0.66 (0.52–0.85)   | 0.001                | 0.67 (0.52–0.85)   | 0.001                |
| Other                           | 1.06 (0.77–1.45)   | 0.732                | 1.05 (0.78–1.43)   | 0.742                |
| Differentiation                 |                    |                      |                    |                      |
| Well                            | 1.00 (reference)   |                      |                    |                      |
| Moderately differentiated       | 0.96 (0.71–1.31)   | 0.805                |                    |                      |
| Poorly differentiated           | 0.98 (0.72–1.33)   | 0.884                |                    |                      |
| Undifferentiated                | 0.84 (0.49–1.45)   | 0.535                |                    |                      |
| Unknown                         | 1.06 (0.75–1.50)   | 0.731                |                    |                      |
| Position                        |                    |                      |                    |                      |
| Bronchus                        | 1.00 (reference)   |                      | 1.00 (reference)   |                      |
| Lobe                            | 1.44 (0.49–4.27)   | 0.509                | 1.42 (0.48–4.20)   | 0.526                |
| Overlapping lesion              | 1.80 (0.53–6.05)   | 0.344                | 1.77 (0.53–5.97)   | 0.356                |
| Unknown                         | 0.75 (0.25–2.30)   | 0.616                | 0.75 (0.24–2.30)   | 0.749                |
| AJCC T status                   |                    |                      |                    |                      |
| T1                              | 1.00 (reference)   |                      | 1.00 (reference)   |                      |
| T2                              | 1.62 (1.28–2.06)   | < 0.001              | 1.61 (1.27–2.04)   | < 0.001              |
| T3                              | 1.18 (0.89–1.56)   | 0.244                | 1.17 (0.89–1.55)   | 0.257                |
| T4                              | 0.76 (0.60–0.97)   | 0.029                | 0.76 (0.60–0.97)   | 0.025                |
| AJCC N status                   |                    |                      |                    |                      |
| N0                              | 1.00 (reference)   |                      | 1.00 (reference)   |                      |
| N1                              | 1.46 (1.23–1.90)   | 0.004                | 1.45 (1.12–1.88)   | 0.005                |
| N2                              | 0.81 (0.66–0.98)   | 0.029                | 0.80 (0.66–0.97)   | 0.02                  |
| N3                              | 0.55 (0.37–0.84)   | 0.005                | 0.55 (0.36–0.83)   | 0.005                |
| AJCC M status                   |                    |                      |                    |                      |
| M1a                             | 1.00 (reference)   |                      | 1.00 (reference)   |                      |
| M1b                             | 1.25 (0.97–1.61)   | 0.088                | 1.24 (0.96–1.60)   | 0.002                |
| M1                             | 1.04 (0.84–1.30)   | 0.705                | 1.04 (0.84–1.29)   | 0.723                |
| Lymph-nodes dissection          |                    |                      |                    |                      |
| No                              | 1.00 (reference)   |                      | 1.00 (reference)   |                      |
| Yes                             | 15.47 (12.91–18.54)| < 0.001             | 15.32 (12.82–18.30)| < 0.001             |
| Radiation                       |                    |                      |                    |                      |
| No                              | 1.00 (reference)   |                      | 1.00 (reference)   |                      |
| Yes                             | 1.31 (1.09–1.58)   | 0.005                | 1.30 (1.08–1.56)   | 0.005                |
| Chemotherapy                    |                    |                      |                    |                      |
| No                              | 1.00 (reference)   |                      |                    |                      |
| Yes                             | 0.95 (0.79–1.13)   | 0.537                |                    |                      |

Impact of surgery types on survival outcomes in IV NSCLC patients

Kaplan-Meier analyses and log-rank test were used in the matched population, patients who underwent lobectomy enjoyed longer CSS and OS compared with sub-lobar resection. The median
CSS time was 29 months for patients who underwent lobectomy and 18 months for patients who received sub-lobar resection after PSM (HR = 0.70, 95% CI 0.61–0.80, P < 0.001) (Fig. 2A). The median OS was 25 and 16 months in lobectomy group and sub-lobar resection group (HR = 0.73, 95% CI 0.65–0.83, P < 0.001) (Fig. 2B), respectively. The 1, 2 and 3-year survival rate after PSM also favored the lobectomy group. (Table 3)

### Table 3

| Characteristic | Cancer Specific Survival | Overall Survival |
|----------------|--------------------------|------------------|
|                | Sub-lobectomy VS. Lobectomy | P value | Sub-lobectomy VS. Lobectomy | P value |
| 1-year survival rate | 59.0% vs. 72.7% | < 0.001 | 56.7% vs. 70.3% | < 0.001 |
| 2-year survival rate | 43.2% vs. 54.9% | < 0.001 | 40.9% vs. 51.5% | < 0.001 |
| 3-year survival rate | 31.9% vs. 44.8% | 0.001 | 29.1% vs. 41.0% | 0.001 |

Primary tumor lobectomy as an independent prognostic factor for survival in IV NSCLC patients

In multivariate Cox analysis (Table 4) of the matched population, lobectomy persisted to be independently associated with better CSS (HR = 0.67, 95% CI 0.58–0.77, P < 0.001) and OS (HR = 0.69, 95% CI 0.61–0.79, P < 0.001). Age, gender, TNM stage, histology, differentiation, lymph node dissections, chemotherapy, radiotherapy were all independent factors for survival of stage IV NSCLC patients.

### Table 4

| Characteristic | Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis |
|----------------|---------------------|-----------------------|---------------------|-----------------------|
|                | Cancer Specific Survival | Overall Survival | Cancer Specific Survival | Overall Survival |
|                | HR (95%CI) | P value | HR (95%CI) | P value |
| Age            | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| < 60           | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 60–75          | 1.13 (0.97–1.32) | 0.112 | 1.22 (1.04–1.43) | 0.017 |
| > 75           | 1.27 (1.04–1.55) | 0.02 | 1.53 (1.24–1.90) | < 0.001 |
| Gender         | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Male           | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Female         | 0.67 (0.59–0.77) | < 0.001 | 0.72 (0.62–0.82) | < 0.001 |
| Histology      | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Squamous cell carcinoma | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Adenocarcinoma | 0.72 (0.59–0.87) | 0.001 | 0.80 (0.65–0.98) | 0.03 |
| Other          | 0.93 (0.73–1.18) | 0.54 | 0.86 (0.67–1.11) | 0.245 |
| Differentiation | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Well           | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Moderately differentia ted | 1.42 (1.09–1.84) | 0.01 | 1.29 (0.99–1.70) | 0.061 | 1.34 (1.05–1.71) | 0.018 | 1.24 (0.97–1.59) |
|---------------------------|------------------|------|------------------|-------|------------------|-------|------------------|
| Poorly differentia ted    | 1.87 (1.45–2.41) | < 0.001 | 1.49 (1.14–1.95) | 0.003 | 1.81 (1.43–2.29) | < 0.001 | 1.45 (1.13–1.85) |
| Undifferentiated           | 2.49 (1.67–3.70) | < 0.001 | 2.12 (1.39–3.24) | < 0.001 | 2.47 (1.71–3.57) | < 0.001 | 2.10 (1.42–3.11) |
| Unknown                   | 1.73 (1.31–2.28) | < 0.001 | 1.41 (1.06–1.88) | 0.018 | 1.60 (1.24–2.08) | < 0.001 | 1.31 (1.00–1.047) |
| Position                  | Bronchus         | 1.00 (reference) | / | / | 1.00 (reference) | / | / |
| Lobe                      | 1.61 (0.52–5.02) | -0.409 | / | / | 1.39 (0.52–3.72) | 0.51 | / |
| Overlapping lesion         | 2.78 (0.83–9.29) | 0.097 | / | / | 2.36 (0.82–6.80) | 0.113 | / |
| Unknown                   | 1.54 (0.49–4.86) | 0.462 | / | / | 1.28 (0.47–3.47) | 0.631 | / |
| AJCC T status             | T1               | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
|                           | T2               | 1.46 (1.21–1.77) | < 0.001 | 1.42 (1.17–1.72) | < 0.001 | 1.38 (1.16–1.65) | < 0.001 | 1.35 (1.13–1.62) |
|                           | T3               | 1.47 (1.18–1.84) | 0.001 | 1.52 (1.20–1.92) | < 0.001 | 1.40 (1.14–1.72) | 0.001 | 1.45 (1.17–1.81) |
|                           | T4               | 1.59 (1.32–1.93) | < 0.001 | 1.49 (1.22–1.82) | < 0.001 | 1.48 (1.24–1.77) | < 0.001 | 1.44 (1.19–1.73) |
| AJCC N status             | N0               | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
|                           | N1               | 1.64 (1.32–2.02) | < 0.001 | 1.78 (1.43–2.21) | < 0.001 | 1.48 (1.21–1.82) | < 0.001 | 1.66 (1.35–2.06) |
|                           | N2               | 1.83 (1.58–2.13) | < 0.001 | 1.83 (1.55–2.15) | < 0.001 | 1.72 (1.49–1.99) | < 0.001 | 1.77 (1.51–2.06) |
|                           | N3               | 1.98 (1.48–2.65) | < 0.001 | 2.04 (1.50–2.76) | < 0.001 | 1.91 (1.45–2.52) | < 0.001 | 2.02 (1.51–2.001) |
| AJCC M status             | M1a              | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
|                           | M1b              | 1.50 (1.20–1.87) | < 0.001 | 1.44 (1.14–1.81) | 0.002 | 1.49 (1.21–1.85) | < 0.001 | 1.47 (1.18–1.93) |
|                           | M1               | 1.45 (1.20–1.74) | < 0.001 | 1.43 (1.18–1.74) | < 0.001 | 1.44 (1.21–1.72) | < 0.001 | 1.44 (1.20–1.74) |
| Primary surgery           | Lobectomy        | 0.70 (0.61–0.80) | < 0.001 | 0.67 (0.58–0.77) | < 0.001 | 0.73 (0.65–0.83) | < 0.001 | 0.69 (0.61–0.79) |
|                           | Lymph nodes      | 0.10 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
|                           | dissection       | 0.001 | 0.76 (0.66–0.88) | < 0.001 | 0.78 (0.68–0.89) | < 0.001 | 0.74 (0.65–0.86) |
| Radiation                 | No               | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
|                           | Yes              | 0.79 (0.69–0.91) | 0.001 | 0.76 (0.66–0.88) | < 0.001 | 0.78 (0.68–0.89) | < 0.001 | 0.74 (0.65–0.86) |
| Chemotherapy              | No               | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
|                           | Yes              | 1.39 (1.21–1.60) | < 0.001 | 1.33 (1.14–1.55) | < 0.001 | 1.36 (1.19–1.55) | < 0.001 | 1.31 (1.13–1.52) |
| PSM, propensity score matching; NSCLC, non-small cell lung cancer; LN, lymph node; AJCC, American Joint Committee on Cancer
Impact of sub-lobar resection on survival outcomes in IV NSCLC patients

We divided sub-lobar resection population into wedge resection and segmentectomy groups, the PSM analysis was conducted to balance the demographic information, which was shown in Supplementary materials. Kaplan-Meier analyses and log-rank test were used in the matched population, patients who underwent wedge resection had similar CSS and OS compared with segmentectomy. The median CSS time was 16 months for patients who underwent wedge resection and 17 months for patients who received segmentectomy after PSM (HR = 0.96, 95% CI 0.70–1.31, P = 0.490) (Fig. 2C). The median OS was 14 and 16 months in wedge resection group and segmentectomy group (HR = 0.96, 95% CI 0.71–1.30, P = 0.390) (Fig. 2D), respectively. The 1, 2 and 3-year survival rate after PSM also showed no difference between the sub-lobar group. (Table 5)

|                | Cancer Specific Survival | Overall Survival |
|----------------|--------------------------|------------------|
|                | Wedge resection VS. Segmentectomy | P value | Wedge resection VS. Segmentectomy | P value |
| 1-year survival rate | 54.7% vs. 61.7%         | 0.103           | 51.6% vs. 61.0%               | 0.103   |
| 2-year survival rate | 42.7% vs. 41.7%         | 0.779           | 40.3% vs. 40.4%               | 0.792   |
| 3-year survival rate | 32.1% vs. 32.2%         | 0.876           | 29.3% vs. 30.1%               | 0.876   |

Impact of lymph node dissection on survival outcomes in IV NSCLC patients

We explore whether lymph node dissection would provide a further survival benefit for stage IV NSCLC patients. According to the multivariate Cox analysis (Table 4) of the matched population, lymph node dissection was independently associated with better CSS (HR = 0.76, 95% CI 0.66–0.88, P < 0.001) and OS (HR = 0.74, 95% CI 0.65–0.86, P < 0.001). We confirmed this result in different types of surgery and found lymph node dissection group persist to have better survival outcomes both in lobectomy group and sub-lobar resection population. (Fig. 3A-D) We further divided all patients into two groups according to lymph node dissection number (< 9 or > = 9). (Fig. 4A-D) The results showed over 9 lymph node dissection only improved survival in sub-lobar resection population (CSS HR = 0.66, 95% CI 0.50–0.87, P = 0.011), but not in lobectomy patients (CSS HR = 0.97, 95% CI 0.70–1.35, P = 0.89).

Subgroup analysis

We further explored whether lobectomy was associated with better survival outcomes in different
subtypes of populations. Both CSS (Fig. 5A) and OS (Fig. 5B) outcomes showed similar results. Except for stage T4 and brain metastasis patients, all subtype of NSCLC patients would benefit more from lobectomy than sub-lobar resection.

**Discussion**

There is growing evidence to support the value of primary tumor resection for advanced NSCLC patients in recent years. However, no study with the primary aim to compare survival outcomes in relation to surgical strategies (lobectomy or sub-lobar resection) were found. Few evidences for best surgery strategy could be referred when surgeons performed operation on metastasis NSCLC patients. This is a population-based propensity score matching study to assess the value of lobectomy or sub-lobar resection in stage IV NSCLC patients. The results indicated that lobectomy can independent significantly improve both cancer specific and overall survival rate compared with sub-lobar resection. Subgroup analysis revealed that comparing with sub-lobar resection, except for stage T4 patients, all subgroup patients would benefit from lobectomy.

According to National Comprehensive Cancer Network (NCCN) guidelines, patients who have single brain or adrenal metastasis, but the primary tumor is T1-2, N0-1 or T3, N0, local treatment of the metastasis followed by resection of the primary tumor is recommended.[12] The guidelines also recommend contralateral lung nodule can be resected. However, published evidences related to local management strategies for stage IV NSCLC are generally single-institution retrospective studies. As such, surgeons have extremely limited evidence to provide a patient an estimate of their prognosis with an aggressive therapy. Yang et al. [13] explored the treatment effect of surgery for metastasis NSCLC with the use of National Cancer Date Base (NCDB), indicating operative for cT1-2, N0-1, M1 or cT3, N0, M1 disease is associated with a 5-year survival of 25%, supporting guidelines that recommend surgery for very select patients with stage IV disease. In the subgroup analysis, comparing with lobectomy, pneumonectomy (HR = 1.58, 95% CI 1.31–1.90, P < 0.001), segmentectomy (HR = 1.36, 95% CI 1.08–1.71, P = 0.009) and wedge resection (HR = 1.70, 95% CI 1.55–1.88, P < 0.001) were all associated with worse survival outcomes in stage IV NSCLC patients. It is noticeable, this subgroup analysis did not balance the patients’ baseline characters, potential
patient selection bias could be existed. The proper surgery type for stage IV NSCLC patients remains to be answered. Based on SEER database and using propensity score matching analysis, our study found that lobectomy should be considered in majority surgery for stage IV NSCLC, except for stage T4 patients, and lymph node dissection may further provide survival benefit.

The role of surgery for advanced stage NSCLC is always commonplace for diagnostic and palliative purposes.[14, 15] As personalized medicine has taken a more prominent role in the care of advanced NSCLC patients and treatment decisions are now based on histological molecular subtypes, surgeons are more commonly performing operations to acquire adequate tissue for enabling detailed subtyping of NSCLC. Sub-lobar resection is enough to get adequate biopsy for diagnostic and palliative purposes; however, lobectomy and lymph node dissection means a more aggressive comprehensive reduction of primary tumor, which might be associated with a better survival outcome. Mitchell et al. [5] found that T stage is also the significant prognostic factor in stage IV NSCLC patients, and comprehensive local consolidative therapy would bring survival benefit both according to OS (HR = 0.67, 95% CI 0.46–0.97, P = 0.034). These evidences also supported a more aggressive and thorough local treatment strategy for metastasis NSCLC.

Oligometastatic NSCLC is one of the most proper indications to receive local consolidative therapy. [16] Ashworth et al [17] indicated survival outcomes for patients with oligometastatic NSCLC are highly variable, and half of patients progress within approximately 12 months; however, long-term survivors do exist. Definitive treatment of the primary lung tumor and low-burden thoracic tumors are strongly associated with improved long-term survival. Many studies have focus on local treatments for oligometastatic NSCLC, with the use of surgery and radiation, both for primary tumor and metastasis sites. Numerous single institution studies have demonstrated that surgical management of patients with oligometastatic NSCLC to the brain, adrenal gland and contralateral lung is associated with superior long-term survival.[18–20] Although surgery are not recommended by NCCN guidelines for management of metastatic NSCLC with pleural dissemination,[12] several cohorts also observed survival benefit for this population.[21] In this population based analysis, we found except for stage T4 patients, all subgroup patients would significant gain more survival benefit from lobectomy than
sub-lobar resection. However, clinical information of oligometastatic NSCLC and patients with pleural dissemination were not available in SEER database, we were unable to verify the treatment effect of lobectomy on these populations. Further real-world studies should focus more on this population. Several potential mechanisms may explain the survival benefit of the aggressive surgical strategy. First, possible larger and comprehensive extend resection would reduce the de novo resistant malignant cells that cannot be killed or inhibited by initial and maintenance systemic therapy, in consequence, life expectancy is prolonged.[22, 23] Second, thorough primary tumor resection would potentiate the effects of perioperative systemic therapy; for example, in a mouse model, after neoadjuvant immunotherapy, these mice received primary tumor resection could get the long survival, while mice did not receive local treatment have a reduced survival time.[24] Third, primary tumor after systemic therapy would promote the growth of distant micrometastatic,[25] by reducing the primary tumor burden in maximum, the growth of distant micrometastatic disease can also be decreased. Notably, these mechanisms are not mutually exclusive, and more than one could contribute to the benefits of lobectomy for advanced NSCLC. Although this population-based analysis suggested the long-term survival beneficial clinical efficacy of lobectomy and lymph node dissection for patients with stage IV NSCLC, the data should be interpreted with caution as: first, information on preoperative comorbidities for patients were lacking which might lead to a selection bias for the treatment choice; second, detailed information and distribution of patients’ metastatic disease is not available, and this would impede us to explore whether oligometastasis disease will affect the benefit of lobectomy; third, data on systemic therapies were not available. This lack of information regarding target therapies and immunotherapy is a limitation of the current study; Although, the number of stage IV patients that underwent primary tumor resection is limited in each medical center, to explore the curative effect of lobectomy for these patients are challenging, SEER database is the only comprehensive population-based database with open access worldwide providing the most ideal approach to study the survival of such patients. Prospective randomized trials are needed to further validate the benefit of surgery types in metastasis NSCLC patients.
Conclusions
In conclusion, our study showed lobectomy for primary tumor may further improve the survival of stage IV NSCLC patients compared with sub-lobar resection. Future clinical trials should focus on optimal candidates for such surgery in metastasis NSCLC patients.

Abbreviations
Non-small cell lung cancer (NSCLC); Epidemiology and End Results (SEER); American Joint Committee on Cancer (AJCC); Collaborative Stage (CS); Propensity-score matching (PSM); progression free survival (PFS); Overall survival (OS); Cancer specific survival (CSS); Kaplan Meier (K-M); Hazard ratio (HR); Confidence intervals (CI); National Cancer Date Base (NCDB).

Declarations

Ethics approval and consent to participate
This study is approved by the ethics committee of the First Affiliated Hospital of Guangzhou Medical University. The committee of the First Affiliated Hospital of Guangzhou Medical University waiver the consent for its retrospective nature.

Consent for publication
All authors agree with publication

Availability of data and material
For original deidentified individual patient data please contact drjianxing.he@gmail.com. Data will be made available for a period of 5 years after the publication date.

Competing interests
None

Funding
This study is supported by the following funding: National Key R&D Program of China (No.2017YFC0907900/2017YFC0907903); China National Science Foundation (Grant No. 81871893); Key Project of Guangzhou Scientific Research Project (Grant No. 201804020030); High-level university construction project of Guangzhou medical university (Grant No. 20182737, 201721007, 201715907, 2017160107); National key R & D Program (Grant No. 2017YFC0907903 & 2017YFC0112704) and the Guangdong high level hospital construction "reaching peak“ plan.

The funders had no role in the design and conduct of the study; collection, management, analysis,
and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Authors' contributions
Conception and design: H-L, Y-Z, W-L, J-H; (II) Administrative support: J-H, W-L, J-L; (III) Provision of study materials: H-L, Y-Z, S-X, B-C; (IV) Collection and assembly of data: W-W, J-H, C-L, Y-L, G-L-, Z-H; (V) Data analysis and interpretation: H-L, J-L, J-H; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors

Acknowledgements
None

References
1. Siegel RL, Miller KD, Jemal A, Cancer statistics, 2018. CA Cancer J Clin, 2018. 68(1): p. 7–30.
2. Jemal A, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.
3. Morgensztern D, et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5(1):29–33.
4. Cancer Fact and Figs. 2017. Atlanta: American Cancer Society. 2017 [cited 2017; Available from: .
5. Mitchell KG, et al., Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer. Clin Lung Cancer, 2019.
6. Arrieta O, et al. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study. Lung Cancer. 2019;130:67–75.
7. Gomez DR, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-
Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019;37(18):1558–65.

8. Abdel-Rahman O. Outcomes of Surgery as Part of the Management of Metastatic Non-Small-Cell Lung Cancer: A Surveillance, Epidemiology and End Results Database Analysis. Cancer Invest. 2018;36(4):238–45.

9. David EA, et al. The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(11):1636–45.

10. Sun Z, et al. Effects of primary tumor resection on the survival of patients with stage IV extrathoracic metastatic non-small cell lung cancer: A population-based study. Lung Cancer. 2019;129:98–106.

11. Doll KM, Rademaker A, Sosa JA. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. JAMA Surg. 2018;153(6):588–9.

12. Ettinger DS, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018;16(7):807–21.

13. Yang CJ, et al. Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis. Lung Cancer. 2018;115:75–83.

14. Cooke DT, et al. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. J Thorac Cardiovasc Surg. 2014;148(1):36–40.

15. Bell D, Wright G. A retrospective review of the palliative surgical management of malignant pleural effusions. BMJ Support Palliat Care. 2014;4(2):161–6.

16. Ashworth AB, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014;15(5):346–55.

17. Ashworth A, et al. Is there an oligometastatic state in non-small cell lung cancer? A
systematic review of the literature. Lung Cancer. 2013;82(2):197–203.

18. Gray PJ, et al. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer. 2014;85(2):239–44.

19. Mercier O, et al. Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130(1):136–40.

20. Congedo MT, et al. Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience. J Thorac Cardiovasc Surg. 2012;144(2):444–52.

21. Okamoto T, et al. Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy. Eur J Cardiothorac Surg. 2012;41(1):25–30.

22. Jabbour SK, et al. Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2015;92(3):627–33.

23. Kanzaki H, et al. Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy. Int J Clin Oncol. 2016;21(5):853–61.

24. Liu J, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016;6(12):1382–99.

25. Twyman-Saint Victor C, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7.

Figures
Figure 1
Flow chart of patient screening

Stage IV NSCLC patients in SEER database (476,757)

Stage IV NSCLC patients met the criteria (24,268)

Stage IV NSCLC patients underwent primary tumor resection (4,114)

Propensity score matching according to different types of surgery

Exclusion criteria:
Less than 18 years old;
Unknown TNM stage;
Unknown survival months;
Unknown treatment modality;
Not the first tumor;
Not only one tumor

sub-lobectomy (644)  lobectomy (644)
Figure 2

Kaplan-Meier plot of survival outcomes for stage IV NSCLC patients according to surgery types. (A) Cancer specific survival of lobectomy versus sublobar resection; (B) Overall survival of lobectomy versus sublobar resection; (C) Cancer specific survival of wedge resection versus segmentectomy; (D) Overall survival of wedge resection versus segmentectomy;
Figure 3

The impact of lymph node dissection on survival outcomes. (A) Cancer specific survival of lobectomy; (B) Overall survival of lobectomy; (C) Cancer specific survival of sub-lobar resection; (D) Overall survival of sub-lobar resection.
Figure 4

The impact of lymph node dissection number on survival outcomes. (A) Cancer specific survival of lobectomy; (B) Overall survival of lobectomy; (C) Cancer specific survival of sub-lobar resection; (D) Overall survival of sub-lobar resection.
### Figure 5

Subgroup analysis for stage IV NSCLC patients according to surgery types. (A) Cancer specific survival; (B) Overall survival

| Subgroup | Median Survival (mo) | 25th Quartile | P-value |
|----------|----------------------|---------------|---------|
| Overall  | 11.5 (9.5 - 15.5)    | 8.0 (7.0 - 10.0) | <0.001 |
| Age      |                      |               |         |
| Male     | 12.0 (9.5 - 15.5)    | 8.5 (7.0 - 11.0) | <0.001 |
| Female   | 11.0 (9.5 - 15.0)    | 8.0 (7.0 - 10.0) | <0.001 |
| Location |                      |               |         |
| NSCLC    | 12.0 (9.5 - 15.5)    | 8.5 (7.0 - 11.0) | <0.001 |
| Other    | 11.0 (9.5 - 15.0)    | 8.0 (7.0 - 10.0) | <0.001 |
| Stage    |                      |               |         |
| IV       | 12.0 (9.5 - 15.5)    | 8.5 (7.0 - 11.0) | <0.001 |
| III      | 11.0 (9.5 - 15.0)    | 8.0 (7.0 - 10.0) | <0.001 |
| Histology|                      |               |         |
| Squamous | 12.0 (9.5 - 15.5)    | 8.5 (7.0 - 11.0) | <0.001 |
| Adenocarcinoma | 11.0 (9.5 - 15.0) | 8.0 (7.0 - 10.0) | <0.001 |
| Other    | 10.5 (9.5 - 15.5)    | 8.0 (7.0 - 10.0) | <0.001 |
| Surgery |                      |               |         |
| Lung     | 12.0 (9.5 - 15.5)    | 8.5 (7.0 - 11.0) | <0.001 |
| Thoracic | 11.0 (9.5 - 15.0)    | 8.0 (7.0 - 10.0) | <0.001 |
| Thoracic redo | 10.5 (9.5 - 15.0) | 8.0 (7.0 - 10.0) | <0.001 |

### Table A

| Subgroup | Median Survival (mo) | 25th Quartile | P-value |
|----------|----------------------|---------------|---------|
| Overall  | 11.5 (9.5 - 15.5)    | 8.0 (7.0 - 10.0) | <0.001 |
| Age      |                      |               |         |
| Male     | 12.0 (9.5 - 15.5)    | 8.5 (7.0 - 11.0) | <0.001 |
| Female   | 11.0 (9.5 - 15.0)    | 8.0 (7.0 - 10.0) | <0.001 |
| Location |                      |               |         |
| NSCLC    | 12.0 (9.5 - 15.5)    | 8.5 (7.0 - 11.0) | <0.001 |
| Other    | 11.0 (9.5 - 15.0)    | 8.0 (7.0 - 10.0) | <0.001 |
| Stage    |                      |               |         |
| IV       | 12.0 (9.5 - 15.5)    | 8.5 (7.0 - 11.0) | <0.001 |
| III      | 11.0 (9.5 - 15.0)    | 8.0 (7.0 - 10.0) | <0.001 |
| Histology|                      |               |         |
| Squamous | 12.0 (9.5 - 15.5)    | 8.5 (7.0 - 11.0) | <0.001 |
| Adenocarcinoma | 11.0 (9.5 - 15.0) | 8.0 (7.0 - 10.0) | <0.001 |
| Other    | 10.5 (9.5 - 15.5)    | 8.0 (7.0 - 10.0) | <0.001 |
| Surgery |                      |               |         |
| Lung     | 12.0 (9.5 - 15.5)    | 8.5 (7.0 - 11.0) | <0.001 |
| Thoracic | 11.0 (9.5 - 15.0)    | 8.0 (7.0 - 10.0) | <0.001 |
| Thoracic redo | 10.5 (9.5 - 15.0) | 8.0 (7.0 - 10.0) | <0.001 |